A Study Assessing GW870086's Potential to Cause Skin Thinning

NCT01381445 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

20

Enrollment

INDUSTRY

Sponsor class

Conditions

Dermatitis, Atopic

Interventions

DRUG: GW870086 0.2%
DRUG: GW870086 2%
DRUG: Clobetasol Propionate
DRUG: Placebo

Sponsor

GlaxoSmithKline